Welcome to our dedicated page for Liquidia Corporation SEC filings (Ticker: LQDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Liquidia Corporation (NASDAQ: LQDA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Delaware corporation focused on biopharmaceutical products for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH‑ILD), Liquidia uses these filings to report financial results, material agreements, governance changes and other significant events.
Investors can review Forms 10‑K and 10‑Q for detailed discussions of Liquidia’s business, including its PRINT® technology platform, the commercialization of YUTREPIA™ (treprostinil) inhalation powder, development of the investigational L606 treprostinil liposome inhalation suspension, and promotion of generic Treprostinil Injection under a profit‑sharing agreement with Sandoz. These periodic reports typically include segment information, research and development spending, risk factors related to PAH and PH‑ILD markets, and descriptions of key contracts.
Current reports on Form 8‑K highlight specific events such as quarterly earnings releases, financing transactions under the revenue interest financing agreement with HealthCare Royalty Partners IV, L.P. (HCR), entry into the exclusive license with Vectura for the nebulizer device used with L606, leases for expanded manufacturing facilities in Morrisville, North Carolina, and outcomes of annual stockholder meetings. Other 8‑K filings may document executive appointments, compensation arrangements and other governance matters.
Users can also monitor proxy statements and Form 4 insider transaction reports to understand board elections, advisory votes on executive compensation and equity awards to officers and directors. Stock Titan’s interface combines these documents with AI‑powered summaries that explain complex sections of long filings, highlight key changes from prior periods and help clarify how new agreements, clinical developments or financing structures may affect Liquidia’s operations and capital structure.
With real‑time updates from EDGAR and structured access to historical filings, this page serves as a central resource for analyzing Liquidia’s regulatory history, capital markets activity and disclosures related to its treprostinil‑based therapies for PAH and PH‑ILD.
Liquidia (LQDA) insider transaction: The company’s Chief Accounting Officer reported two open‑market sales of common stock on 11/07/2025. The sales were 8,342 shares at $25.16 and 20,662 shares at $25.06. Following these transactions, the reporting person beneficially owned 155,334 shares, held directly.
Footnote details list unvested and plan-related holdings, including 1,884 unvested RSUs from a 01/16/2022 grant, 15,625 unvested RSUs from a 01/25/2023 grant, 32,110 unvested RSUs from a 01/11/2024 grant, 50,861 RSUs granted on 01/11/2025 (none vested), 25,000 RSUs granted on 07/01/2025 (none vested), and 3,527 shares acquired under the 2020 Employee Stock Purchase Plan.
Liquidia Corporation (LQDA) filed a Form 4 showing stock sales by Chief Medical Officer Dr. Rajeev Saggar. On 11/05/2025, he sold 4,918 shares of common stock at $27 and 66,463 shares at $27. Following these transactions, his beneficial ownership stood at 176,549 shares, held directly.
The filing notes equity awards and purchases: 26,041 unvested RSUs from an 83,333 grant dated January 11, 2023; 31,777 unvested RSUs from a 56,492 grant dated January 11, 2024; and 71,780 RSUs granted on January 11, 2025, none of which had vested as of the filing date. It also includes 2,221 shares acquired under the company’s 2020 Employee Stock Purchase Plan.
Liquidia Corporation reported its Q3 2025 results, driven by the first full quarter of YUTREPIA commercialization. Total revenue reached $54.3 million, up from $4.4 million a year ago, including $51.7 million in product sales from YUTREPIA and $2.7 million in service revenue from the Sandoz promotion agreement.
The company generated $1.8 million of operating income as higher sales offset elevated selling, general and administrative costs of $40.1 million. Net loss narrowed to $3.5 million (basic and diluted EPS $(0.04)), primarily due to $6.9 million in interest expense that outweighed $1.6 million in interest income.
As of September 30, 2025, cash and cash equivalents were $157.5 million, with long‑term debt (including current portion) of $192.5 million. Shares outstanding were 86,819,212. YUTREPIA was FDA‑approved on May 23, 2025 for PAH and PH‑ILD and launched June 2, 2025, underpinning the quarter’s product revenue. Management noted minimum cash covenants of $15.0 million under its revenue interest financing agreement and stated it has sufficient liquidity for at least the next twelve months.
Liquidia Corporation furnished a Current Report announcing it issued a press release with financial results for the quarter ended September 30, 2025, and provided a corporate update.
The press release is included as Exhibit 99.1. The information under Item 2.02 is expressly stated as furnished and not deemed filed under the Exchange Act.
Liquidia Corporation entered an exclusive license with Vectura Limited to develop, manufacture and commercialize in the United States treprostinil products, including Liquidia’s L606, administered via Vectura’s nebulizer device for PAH and PH‑ILD. Vectura will manufacture and supply clinical and commercial devices.
Financial terms include an upfront $2,000,000 payment, development milestones of up to $12,000,000, sales milestones of up to $92.5 million, and royalties at middle single‑digit rates on U.S. sales. Liquidia also secured rights of first negotiation for additional territories and indications. The agreement continues on a country‑ and product‑specific basis through the applicable royalty term and includes customary termination rights for breach, bankruptcy, program discontinuation, feasibility determinations, related agreement terminations, effort requirements, and patent challenges.
Liquidia Corporation (LQDA) Chief Business Officer filed a Form 4 reporting a sale of 692 shares of common stock at $22.93 on October 27, 2025, executed pursuant to a Rule 10b5-1 plan adopted on December 15, 2023. The filing states the shares were sold to cover taxes tied to the settlement of RSUs granted on July 6, 2023.
Following the transaction, the officer beneficially owned 174,998 shares directly. Holdings include 10,937 unvested RSUs from the July 6, 2023 grant, 22,268 unvested RSUs from a January 11, 2024 grant, and 61,895 RSUs granted on January 11, 2025 (none vested as of the filing date), plus 11,586 shares acquired under the 2020 Employee Stock Purchase Plan.
Liquidia Corp (LQDA) reported an insider transaction on a Form 4. The Chief Accounting Officer sold 1,073 shares of common stock at $22.93 per share on 10/27/2025 (transaction code S).
The filing notes the sale was made pursuant to a Rule 10b5-1 plan adopted on December 15, 2023 and was executed to cover taxes associated with the settlement of previously granted RSUs. Following the transaction, the reporting person beneficially owns 184,338 shares, held directly.
Liquidia (LQDA): CEO and Director Roger Jeffs reported insider transactions. On 10/10/2025, 13,834 shares of common stock were acquired via the conversion of performance stock units at $0. On 10/13/2025, 20,261 shares were sold at $23.41 under a Rule 10b5-1 plan adopted on December 15, 2023.
After these transactions, direct holdings were 1,032,973 shares. Indirect holdings included 46,595 shares held by the Roger A. Jeffs Living Trust and 1,541,667 shares held by Serendipity BioPharma LLC, over which he has sole voting and dispositive power. The sale was to cover taxes associated with RSU and PSU settlements.
Liquidia (LQDA) reported insider activity by its Chief Business Officer. On 10/10/2025, the officer settled equity awards, converting 3,906 RSUs and 2,474 PSUs into common stock. On 10/13/2025, 3,670 shares were sold at $23.41 under a Rule 10b5-1 plan to cover taxes tied to those settlements. Following these transactions, the officer beneficially owned 175,690 common shares, held directly. RSUs and PSUs convert one-for-one into common stock, with remaining unvested awards continuing on their stated vesting schedules.
Liquidia Corp. (LQDA) insider activity: Chief Medical Officer Dr. Rajeev Saggar reported a PSU conversion and a tax-related sale. On 10/10/2025, 3,530 performance stock units converted into common stock on a one-for-one basis (code M). On 10/13/2025, 5,327 shares were sold at $23.41 (code S) pursuant to a Rule 10b5-1 plan adopted on December 15, 2023.
Following these transactions, the reporting person beneficially owns 247,930 shares, held directly. The sale was disclosed as covering taxes tied to the settlement of RSUs and PSUs initially granted on January 11, 2023 and January 11, 2024. The officer’s role is listed as Chief Medical Officer.
FAQ
What is the current stock price of Liquidia Corporation (LQDA)?
What is the market cap of Liquidia Corporation (LQDA)?
